Target：BC11B
Fields：Transcriptional misregulation in cancer
Gene Name：BCL11B CTIP2 RIT1
Protein Name：B-cell lymphoma/leukemia 11B (BCL-11B) (B-cell CLL/lymphoma 11B) (COUP-TF-interacting protein 2) (Radiation-induced tumor suppressor gene 1 protein) (hRit1)
Human Gene Id：64919
Human Swiss Prot No：Q9C0K0
Mouse Swiss Prot No：Q99PV8
Immunogen：Synthesized peptide derived from human protein . at AA range: 570-650
Specificity：BC11B Polyclonal Antibody detects endogenous levels of protein.
Formulation：Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.
Source：Polyclonal, Rabbit,IgG
Dilution：WB 1:500-2000 ELISA 1:5000-20000
Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration：1 mg/ml
Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)
Observed Band(KD)：98kD
Background：B-cell CLL/lymphoma 11B(BCL11B) Homo sapiens This gene encodes a C2H2-type zinc finger protein and is closely related to BCL11A, a gene whose translocation may be associated with B-cell malignancies. Although the specific function of this gene has not been determined, the encoded protein is known to be a transcriptional repressor, and is regulated by the NURD nucleosome remodeling and histone deacetylase complex. Four alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Aug 2013],
Function：function:Tumor-suppressor protein involved in T-cell lymphomas. May function on the P53-signaling pathway. May be a key regulator of both differentiation and survival during thymocyte development. Repress transcription through direct, TFCOUP2-independent binding to a GC-rich response element.,similarity:Contains 6 C2H2-type zinc fingers.,subunit:Interacts with TFCOUP1, SIRT1, ARP1 and EAR2.,tissue specificity:Highly expressed in brain and in malignant T-cell lines derived from patients with adult T-cell leukemia/lymphoma.,
Subcellular Location：Nucleus .
Expression：Highly expressed in brain and in malignant T-cell lines derived from patients with adult T-cell leukemia/lymphoma.
